Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?
Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral Foundayo, while also committing an additional US$4.50Â billion to expand Indiana manufacturing for its incretin and genetic medicine portfolio. The combination of durable weight-loss data and large-scale production build-out underscores how central obesity and metabol…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
